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Pulmonary arterial hypertension (PAH) is a severe vasculopathy characterized by
the presence of fibrotic lesions in the arterial wall and the loss of small distal
pulmonary arteries. The vasculopathy is accompanied by perivascular inflammation and
increased protease levels, with neutrophil elastase notably implicated in aberrant vascular
remodeling. However, the source of elevated elastase levels in PAH remains unclear. A
major source of neutrophil elastase is the neutrophil, an understudied cell population in
PAH. The principal function of neutrophils is to destroy invading pathogens by means of
phagocytosis and NET formation, but proteases, chemokines, and cytokines implicated
in PAH can be released by and/or prime and activate neutrophils. This review focuses on
the contribution of inflammation to the development and progression of the disease,
highlighting studies implicating neutrophils, neutrophil elastase, and other neutrophil
proteases in PAH. The roles of cytokines, chemokines, and neutrophil elastase in the
disease are discussed and we describe new insight into the role neutrophils potentially
play in the pathogenesis of PAH.
Keywords: neutrophils, neutrophil elastase, pulmonary hypertension, pulmonary arterial hypertension, vascular
remodeling
PULMONARY ARTERIAL HYPERTENSION AND INFLAMMATION
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by thickening,
and progressive occlusion of distal arteries in the lung related to vascular cell dysfunction, and
perivascular inflammation. As a consequence of elevation in pulmonary arterial pressure, the
right ventricle hypertrophies and later becomes dysfunctional leading to right heart failure (1, 2).
Perivascular inflammation has been observed in all subsets of PAH and correlates with clinical
markers of disease progression such as an increase in pulmonary vascular resistance and a
decrease in the 6-min walk test (3, 4). The consequences of perivascular inflammation include
cytokine production by vascular and inflammatory cells, and degradation of the extracellular
matrix (ECM) by proteases (5, 6). Both the increased cytokine production and the peptides
that are released as a result of ECM degradation cause activation and recruitment of circulating
immune cells (6, 7). Neutrophils are among the cells that are recruited, and these cells release
proteolytic enzymes, including neutrophil elastase (NE), that cause vascular injury (8). Although
many aspects of perivascular inflammation can cause progressive PAH, this review will focus
on neutrophils and NE. We will review evidence of neutrophil accumulation in PAH, discuss
the role of NE and other proteases in driving vascular remodeling and highlight potential
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interactions between neutrophils, NE and the key genetic driver
of PAH, bone morphogenetic protein receptor type 2 (BMPR2).
NEUTROPHILS AND PAH
Neutrophils are the predominant circulating leukocyte
population and are important in modulating innate and
adaptive immunity. They are early responders and are recruited
to sites of sterile inflammation and infection by environmental
cues.
Relatively little attention has been given to the role of
neutrophils in the pathogenesis of PAH. Neutrophil and
macrophage perivascular accumulation has been observed
in murine lungs in association with hypoxic pulmonary
hypertension (PH) and in monocrotaline-induced PH in rats (9,
10). It has also been established that the neutrophil to lymphocyte
ratio is increased in PAH patients when compared to healthy
controls (11) and that increased neutrophil to lymphocyte ratio
positively correlates with New York Heart Association (NYHA)
functional class (FC) and predicts event free survival (12, 13). It
is not clear why this relative increase in circulating neutrophils
is associated with PAH progression. However, neutrophils
produce a wide range of substances that could contribute to
vascular remodeling and promote inflammation in PAH. For
example, myeloperoxidase (MPO), a catalyst for reactive oxygen
species (ROS) formation, has recently been implicated in the
pathophysiology of PAH (14). Two independent cohorts of PAH
patients had increased plasma MPO relative to healthy controls
and Mpo−/− mice displayed reduced right ventricular pressures
following hypoxic exposure (14). Interestingly, although MPO
can reduce nitric oxide (NO) bioavailability in other vascular
beds (15), there was no evidence supporting a difference in
NO availability between wild-type and MPO-deficient mice (14).
Instead, activation of a Rho kinase pathway by MPO was found
to drive pulmonary vasoconstriction and SMC proliferation (14).
In addition toMPO and ROS, neutrophils produce proteolytic
enzymes. Activity of these enzymes is tightly controlled by
endogenous inhibitors, but excessive protease activity has
the potential to destroy tissue and cause extensive fibrotic
remodeling, leading to organ failure (16). Indeed neutrophil
proteases are implicated in airway and parenchymal lung diseases
[reviewed by Taggart et al. (17)] and are known to have roles in
systemic vascular pathology (18, 19).
Neutrophil granule proteases include members of the
serine protease family (NE, cathepsin G, proteinase 3) and
matrix metalloproteinases [neutrophil collagenase (MMP-8) and
gelatinase (MMP-9)] (20). Of these proteases, NE has been most
heavily implicated in the pathogenesis of PAH, as described
below.
SOURCES OF NEUTROPHIL ELASTASE IN
PAH
Neutrophils are the dominant cellular source of NE but it
is also produced by macrophages and smooth muscle cells
(SMC) (21–24). There is evidence of both augmented NE
release from neutrophils isolated from PAH patients (25)
and upregulation of endogenous NE in PAH patient SMCs
and in experimental animal models of PH (23, 26, 27).
Macrophages are observed in the plexiform lesions of PAH
patient lungs and activated macrophages release leukotriene
B4, which induces endothelial cell (EC) injury and results in
EC apoptosis, but could also promote neutrophil recruitment
(28). Moreover, in vitro work suggests that human alveolar
macrophages internalize NE through ingestion of apoptotic
neutrophils, and act as a vehicle for the enzyme, transporting it
to the tissues and subsequently releasing the active form (29).
However, further work is required to show conservation
of this mechanism in perivascular or interstitial lung
macrophages.
NE is dispensed by neutrophils during degranulation and
upon release of neutrophil extracellular traps (NETs). NETs
consist of decondensed chromatin decorated with NE and other
antimicrobial proteases. NE plays an important role in NET
release, evidenced by reduced NET formation in the presence of
NE inhibitors and in NE knockout mice (30). Upon stimulation,
NE is discharged from azurophilic granules and translocates
to the nucleus where it contributes to histone degradation,
facilitating chromatin decondensation (30). Depending on the
stimulus, chromatin is then expelled via vesicles (31) or suicidal
NETosis (32), reviewed by Jorch et al. (33).
NETs assist in microbial trapping and killing (32), but non-
infectious roles for NETs are emerging and NETs have been
identified in vascular pathologies such as atherosclerosis and
PAH (34, 35). Detrimental consequences attributed to NETs
include nuclear factor kappa-light-chain-enhancer of activated
B cells-dependent PA EC pathological angiogenesis, release
of the vasoactive agent endothelin-1, and promotion of SMC
proliferation (34). NETs can also directly induce EC cell death
(36) and promote thrombus formation (37). In PAH lung
tissue, markers of NET formation (DNA, myeloperoxidase, and
citrullinated histone H3) have been identified in proximity to
plexiform lesions and circulating DNA levels were elevated in
IPAH patient plasma (34), although this study did not investigate
whether IPAH patient neutrophils are more prone to releasing
NETs.
Studies prior to the identification of NETs had suggested that
binding of NE to DNA inhibited the activity of the protease
(38). However, Kolaczkowska et al. used an in vivo zymography
assay to demonstrate that NE associated with NETs remains
proteolytically active (39). This implies that NE attached to NETs
is shielded from endogenous anti-protease activity and thus high
NET levels in PAH may represent an important source of active
NE.
NEUTROPHIL ELASTASE IN THE
PATHOLOGY OF PAH
Elastolytic activity has been implicated in the pathogenesis
of PAH for over three decades, with evidence of fragmented
internal elastic laminae in the pulmonary arteries of children
with congenital heart defects (40). There is a clear temporal
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relationship between increased NE activity and vascular changes
in PAH experimental rat models (41). Furthermore, inhibition
of NE enzymatic activity not only attenuates the progression of
PAH but can also reverse the disease process in experimental
models. This was first shown in the monocrotaline model
where a progressive and fatal form of PH was reversed
by elastase inhibitors in association with normalization of
hemodynamic changes of PH and structural abnormalities that
included extensive occlusive muscularization (26). Nickel et al.
also demonstrated reversal of hemodynamic and histological
measures of PH in the Sugen/Hypoxia rat model following
treatment with recombinant human elafin (42). Increased
NE activity was demonstrated in the lungs of rats with
Sugen/Hypoxia-induced PH and this was attenuated by elafin
(42). Importantly, relevance to human disease was confirmed
through use of a human pulmonary artery explant model.
Tissue sections containing pulmonary arteries were isolated
from the explanted lungs of PAH patients and treatment with
elafin induced regression of neointimal changes and improved
measures of vessel lumen size (42).
Release of NE can stimulate adverse remodeling by degrading
virtually all the components of the ECM in addition to elastin,
and including collagen, fibronectin, and laminin (43). As a
consequence, degraded ECM releases bioactive peptides and
growth factors such as epidermal growth factor (EGF) and
fibroblast growth factor (FGF), which have both mitogenic
and motogenic effects on SMCs and fibroblasts (44–47).
Additionally, heightened NE activity leads to the activation
of matrix metalloproteinases (MMPs), which could potentiate
ECM degradation, and induction of tenascin C, a glycoprotein
associated with the upregulation of growth factor receptors and
proliferation of SMCs (48). The sub-endothelial deposition of
tenascin C and fibronectin appears to be a chemotactic factor
for PA SMCs, facilitating their migration and the formation of
neointimal lesions (48, 49). Conversely, inhibition of NE leads to
reduced tenascin C, induction of SMC apoptosis, and regression
of pulmonary artery (PA) medial hypertrophy (26).
The role of elastase in vascular remodeling was further
explored using transgenic mice that over-express the S100A4
protein (23, 27). Following infection with the murine herpes
virus, MHV-68, S100A4 mice develop histological features of
human PAH including neointima formation (27). These vascular
lesions display fragmented elastic laminae associated with
heightened lung elastase activity (27). Infusion of recombinant
human elafin, an endogenous elastase inhibitor, reduced the
number and severity of neointimal lesions in this model (23).
Furthermore, using FLAG-tagged elafin, NE was identified as the
serine elastase responsible for the elevation in elastase activity
in the S100A4 lungs (23). While this finding implies that NE is
the dominant target in this model, the relative importance of NE
above other proteases in human disease has not been confirmed
and the potential roles of other proteases will be discussed below.
The source of NE in the S100A4 lungs was localized not
only to neutrophils but also to PA SMCs and, as indicated
above, this finding was conserved in human disease, evidenced
by cultured PA SMCs from IPAHpatients expressing higher levels
of NE than cells from control donor lungs (23). Interestingly, ex
vivo perfusion of S100A4 lungs with porcine pancreatic elastase
suggested that the elastin fibers in these mice were more prone
to degradation (23). This implies that certain viral infections,
and potentially other inflammatory stimuli, may predispose
the vasculature to pathological remodeling upon exposure to
elastase.
NEUTROPHIL ELASTASE AND
PERPETUATION OF INFLAMMATION IN
PAH
In addition to the impact of NE on SMC migration and
proliferation, this enzyme contributes to PAH pathogenesis by
proteolytic modification of cytokines. For example, NE promotes
IL-1β activity by cleaving the pro-isoform of IL-1β in human
coronary ECs, thereby increasing the secretion of the bioactive
form in extracellular vesicles (50). Notably, secretion of active
IL-1β could promote neutrophil survival, an example of positive
regulation of neutrophil activity by cytokines (51).
NE also cleaves CXCL12 (SDF-1 alpha), a chemokine involved
in the regulated release of neutrophils from the bone marrow
(52–54). CXCL12 inactivation would promote mobilization of
neutrophils into the circulation, particularly in the context
of elevated plasma IL-8 levels, as observed in PAH patients
(4, 54). On the other hand, NE can inactivate tumor-necrosis
factor (55) and IL-6 (56), suggesting that there is a balance
that must be maintained between elastase and anti-elastase
activity. The chronic perivascular inflammatory phenotype of
PAH patients characterized by elevated levels of circulating
and tissue cytokines, is consistent with persistent neutrophil
activation. Indeed, many of the cytokines elevated in PAH are
known to enhance neutrophil function and survival andmay thus
perpetuate neutrophil-mediated inflammation (Table 1).
OTHER PROTEASES IMPLICATED IN
TISSUE REMODELING IN PAH
As mentioned above, other neutrophil proteases may contribute
to the vascular remodeling observed in PAH. For example,
MMP-9 expression is upregulated in human plexiform
pulmonary arterial lesions (61) and in lungs isolated from
rats with monocrotaline-induced pulmonary hypertension (62).
Furthermore, transgenic overexpression of human MMP-9
exacerbated monocrotaline-induced pulmonary hypertension in
mice (63). The role of other MMPs and MMP inhibitors in PAH
has been reviewed by Chelladuri et al. (64).
This review has focused mainly on neutrophil proteases,
but it should be noted that many other cells release proteases.
For example, upregulation of MMP-9 has been detected in
natural killer cells from patients with PAH (65) and it is also
released by monocytes and macrophages (66). Further examples
of important non-neutrophil proteases are chymase and tryptase,
the main proteases released by mast cells. Heath and Yacoub (67)
noted increased perivascular mast cell numbers in both primary
and secondary forms of pulmonary hypertension compared to
controls, an observation confirmed more recently by others (68,
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TABLE 1 | Cytokines elevated in PAH and known to alter neutrophil function.
Cytokine Release Priming Adhesion Chemotaxis ROS Survival References
CCL2 x x x x (57)
IL-1α x (58)
IL-1β x x x x x x (4, 58, 59)
IL-4 x (4)
IL-6 x x x (4, 58–60)
IL-8 x x x x (4)
IL-10 x (4)
IL-12 x (4)
Interferon- γ x x x (4)
TNF-α x x x x x x (4, 58)
The x symbols indicate which functions are altered by each cytokine. ROS, reactive oxygen species generation; CCL2, C-C Motif Chemokine Ligand 2, also known as monocyte
chemoattractant protein 1; IL, interleukin; TNF, tumor necrosis factor.
69). Circulating tryptase levels were elevated in PAH patients
compared to controls and correlated with disease severity as
assessed by brain natriuretic peptide level (68). In this study a
small number of patients were treated with mast cell stabilizers,
but there were no changes in clinical endpoints such as 6-min
walk distance or BNP level.
A key question about protease activity in any disease
process is how the protease evades suppression by endogenous
inhibitors. NE is inhibited by several anti-proteases including
α1-antitrypsin, secretory leucocyte peptidase inhibitor (SLPI)
and elafin. On the one hand it is possible that localized
release of the protease simply overcomes anti-protease activity
in the immediate microenvironment. Indeed, markers of pre-
inhibited elastase activity have been reported including the
cleaved fibrinogen product, Aα-Val360 (70). On the other hand,
proteases may be shielded from their inhibitors by attachment
to NETS (discussed above), or via transport in exosomes.
Neutrophil-derived exosomes degrade NE substrates and induce
emphysematous changes in murine lungs following intra-
tracheal administration (71). It is also possible that proteases have
enzyme-independent functions but the beneficial consequences
of elafin treatment in animal models of PH and in lung explant
models (23, 42) would favor the hypothesis that there is an
excess of protease activity. Interestingly, however, elafin may
exert protective effects independently of protease inhibition as
described below.
NEUTROPHILS AND PAH RELATED TO
BMPR2 DEFICIENCY
The bone morphogenetic protein receptor 2 (BMPR2) signaling
pathway has become a key focus of investigation since BMPR2
gene mutations were identified as the main predisposing risk
factor in the heritable forms of PAH (HPAH) (72), with
dysfunction in the signaling pathway present in all subtypes of
PAH (73). However, although present in a high proportion of
HPAH cases—identified in 70% of familial PAH cases (74)—the
autosomal dominant BMPR2 mutation exhibits low penetrance
with 70–80% of those carrying the mutation never developing
PAH (75). This, and the lack of spontaneous PAH in most
heterozygous BMPR2 animal models, implies that a second
insult or background genetic variants are needed for predisposed
individuals to develop PAH. Inflammation has been proposed as
a second hit which promotes adverse remodeling when there is a
loss of BMPR2.
BMPR2 is expressed by all cells in the arterial wall but by
far the highest level of expression is present in endothelial cells
(73). Reduced BMPR2 signaling is related both to excessive
vascular smooth muscle proliferation (76) and exaggerated PA
EC apoptosis (77). A study by Burton et al. (78) investigated the
role of BMPR2 inmaintaining the barrier function of PA ECs and
in suppressing inflammation within the pulmonary vasculature.
Using static and flow-based in vitro systems, they were able to
demonstrate that a reduction in BMPR2 expression facilitated
neutrophil transmigration across the PA EC monolayer and
reported that a lack of BMPR2 led to overexpression of IL-8,
which in turn led to the recruitment of neutrophils. Similarly, loss
of BMPR2 can lead to heightened expression of IL-6, an inducer
of SMC proliferation (79). Taken together, BMPR2 plays a role in
dampening inflammatory signals in the pulmonary vasculature
that could influence neutrophil recruitment and elastase activity.
Conversely, neutrophils may also impact BMPR2 function by
releasing NE and degrading BMP9, an anti-angiogenic ligand
for the BMPR2/ALK1 heterodimer present on PA ECs (80).
BMP9 has been shown to circulate in humans at biologically
active levels (81), maintaining vascular quiescence. Li et al.
showed that BMP9 is readily cleaved by NE, released by activated
neutrophils (80). Further work by this group demonstrated that
the administration of recombinant BMP9 reversed established
PH in BMPR2-deficient mice, overcoming reduced BMPR2
levels, and preventing lung vascular leakage (82). Paradoxically,
Appleby et al. demonstrated that BMP9 could have a pro-
inflammatory role and, in fact, facilitate neutrophil recruitment
to the pulmonary vasculature by activated endothelial cells
(83). However, the mouse model used in that study was acute
endotoxemia, so thismay not relate directly to PAHpathogenesis.
Overall, it appears that inflammation-driven release of NE can
suppress BMPR2 signaling. Nickel and colleagues investigated
the impact of the NE inhibitor elafin on BMPR2 signaling in PAH
(42). In the Sugen/Hypoxia rat model of PH, elafin improved
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pulmonary endothelial expression of apelin, a BMPR2 target
gene. Loss of apelin expression in the pulmonary endothelium
during PAH is associated with the failure to repress the release
of fibroblast growth factor-2 (FGF2) (84). Nickel et al. also
found that in human cells, elafin augmented BMPR2 interactions
with caveolin-1, another downstream target of BMPR2 signaling
(42). Unfortunately, changes in BMP9 levels following elafin
administration were not measured. Nonetheless, the findings
suggest that improving BMPR2 signaling in addition to the
beneficial sequelae of inhibiting NE, described earlier in this
review, could reverse the vascular remodeling observed in
PAH. Interestingly, targeting NE activity may be of particular
importance in patients with BMPR2 mutations, as histological
assessment of pulmonary vessels in such patients demonstrates
a reduction in elastin and fibrillin-1, the two major constituents
of elastic fibers (85). Furthermore, pulmonary artery elastic fibers
from mice with compound Bmpr2/1a mutations were more
susceptible to elastase-mediated degradation of elastic fibers
compared to wild-type mice (85).
SUMMARY
Collectively the studies discussed above implicate the neutrophil
and neutrophil products such as MPO, proteases and NETs in
the pathogenesis of PAH. Neutrophils are attractive candidates
in contributing to vascular changes seen in PAH because they
are among the first cells to arrive at sites of inflammation.
The evidence of increased circulating elastase in PAH patients
and fragmented elastic lamina in PAH vessels, highlights a key
pathogenic role for proteolytic enzymes and in particular NE. NE
has a wide range of targets, but we describe evidence for how it
could contribute to PAH pathogenesis by modulating the activity
of cytokines and degrading ECM releasing growth factors that
promote remodeling. Moreover, the release of NE and NETs is
likely to alter the local inflammatory environment, augmenting
leukocyte responses and further driving inflammation in PAH.
It is also evident that reduced BMPR2 receptor signaling
cooperatively interacts with the sequelae of inflammation
and neutrophil activation in contributing to adverse vascular
remodeling. Figure 1 provides a summary of the role of
neutrophils, NE and NETs in PAH.
While increases in NE activity coincide with changes in
vascular remodeling in animal models, it remains unclear
whether intrinsic neutrophil abnormalities are necessary to
initiate aberrant remodeling in human lungs or whether
alterations in NET and NE release by neutrophils are a
consequence of other features of the disease. To better
understand the role of neutrophils at different stages of
PAH pathogenesis, a longitudinal study to evaluate how they
become increased and activated would be important. However,
FIGURE 1 | Following vascular injury (1), the release of chemokines and chemotactic peptides from surrounding tissue recruits and activates neutrophils (2).
Neutrophils release elastase (3) although it can also be released from activated macrophages that engulf neutrophil elastase (4) and from smooth muscle cells.
Release of neutrophil elastase leads to cleavage of cytokines resulting in the conversion of the pro-to active form of IL-1b, promoting neutrophil survival, and
degradation of CXCL12, favoring release of neutrophils from the bone marrow (5). BMP9 is also cleaved, impacting upon BMPR2 receptor signaling (6). Degradation
of the ECM by elastase (7) releases SMC mitogenic growth factors promoting SMC proliferation (8). Neutrophil elastase is also involved in the release of NETs, which
may induce EC apoptosis (9) and therefore contribute to endothelial dysfunction.
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directly targeting neutrophils as a therapeutic strategy would
be challenging given their vital role in host defense and as
mentioned above, cells other than neutrophils can produce
damaging proteases. Of these proteases, NE provides an attractive
target as evidence from animal models suggests that NE
inhibition has the potential to inhibit aberrant remodeling
of the pulmonary vessels and indirectly dampen persistent
inflammation in PAH. These findings have encouraged initiation
of clinical trials of elastase inhibitors such as elafin for PAH
(NCT03522935). Further, the potential for NE inhibitors such as
elafin to enhance BMPR2 signaling and target pathology driven
by BMPR2 deficiency, identifies these drugs as promising novel
therapies for PAH.
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